Secnidazole-¹³C₂, ¹⁵N₂  (Synonyms: RP-14539-¹³C₂, ¹⁵N₂; PM-185184-¹³C₂, ¹⁵N₂)

Secnidazole-¹³C₂, ¹⁵N₂ is the ¹³C₂, ¹⁵N₂ labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

189.15

C₅¹³C₂H₁₁N¹⁵N₂O₃

3366-95-8

OC(C)C[15N]1C([N+]([O-])=O)=C[15N]=[13C]1[13CH3]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]

  [2]. Petrina MAB, et al. Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017 Oct;47:115-119.  [Content Brief]